| Trial Information . | . |
|---|---|
| Disease | Colorectal cancer |
| Stage of disease/treatment | Metastatic/advanced |
| Prior therapy | More than one prior regimen |
| Type of study | Phase I; 3 + 3 |
| Primary endpoint | Recommended phase II dose, frequency of febrile neutropenia |
| Secondary endpoints | Safety, efficacy |
| Investigator’s analysis | Active but results overtaken by other developments |
| Trial Information . | . |
|---|---|
| Disease | Colorectal cancer |
| Stage of disease/treatment | Metastatic/advanced |
| Prior therapy | More than one prior regimen |
| Type of study | Phase I; 3 + 3 |
| Primary endpoint | Recommended phase II dose, frequency of febrile neutropenia |
| Secondary endpoints | Safety, efficacy |
| Investigator’s analysis | Active but results overtaken by other developments |
| Trial Information . | . |
|---|---|
| Disease | Colorectal cancer |
| Stage of disease/treatment | Metastatic/advanced |
| Prior therapy | More than one prior regimen |
| Type of study | Phase I; 3 + 3 |
| Primary endpoint | Recommended phase II dose, frequency of febrile neutropenia |
| Secondary endpoints | Safety, efficacy |
| Investigator’s analysis | Active but results overtaken by other developments |
| Trial Information . | . |
|---|---|
| Disease | Colorectal cancer |
| Stage of disease/treatment | Metastatic/advanced |
| Prior therapy | More than one prior regimen |
| Type of study | Phase I; 3 + 3 |
| Primary endpoint | Recommended phase II dose, frequency of febrile neutropenia |
| Secondary endpoints | Safety, efficacy |
| Investigator’s analysis | Active but results overtaken by other developments |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
